A phase II study of Becotatug (JMT101) in combination with osimertinib (Osi) in patients (pts) with classical EGFR-mutated non-small cell lung cancer (NSCLC) (BOOSTER Study)

被引：0
|
作者：
Zhang, L. [1 ]
Fang, W. F. [1 ]
Zhao, S. [1 ]
Yu, Y. [2 ]
Yong, T. X. [3 ]
Dong, X. [4 ]
Zhuang, W. [5 ]
Hu, Y. [6 ]
Luo, F. [7 ]
Wang, Q. [8 ]
Chu, Q. [9 ]
Fu, Z. [10 ]
Yao, Y. [11 ]
Ma, X. [12 ]
Ding, C. [13 ]
Hao, J. [14 ]
Yang, X. [14 ]
Wan, X. [14 ]
Li, M. [14 ]
Yang, Y. [14 ]
机构：
[1] Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, Guangzhou, Peoples R China
[2] Harbin Med Univ, Canc Hosp, Dept Med Oncol, Harbin, Peoples R China
[3] Shandong Canc Hosp & Inst, Dept Resp Med, Jinan, Peoples R China
[4] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Thorac Oncol, Wuhan, Peoples R China
[5] Fujian Prov Canc Hosp, Dept Resp Med, Fuzhou, Peoples R China
[6] Hubei Canc Hosp, Dept Oncol, Wuhan, Peoples R China
[7] Sichuan Univ, West China Hosp, West China Sch Med, Lung Canc Ctr, Chengdu, Peoples R China
[8] Jiangsu Prov Hosp Tradit Chinese Med TCM, Dept Resp Med, Nanjing, Peoples R China
[9] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Oncol, Wuhan, Peoples R China
[10] Wuhan Univ, Renmin Hosp, Hubei Gen Hosp, Canc Ctr, Wuhan, Peoples R China
[11] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Oncol, Xian, Peoples R China
[12] Qingdao Univ, Affiliated Qingdao Cent Hosp, Canc Ctr, Qingdao, Peoples R China
[13] Fourth Hosp Hebei Med Univ North Gate, Dept Resp Med, Shijiazhuang, Hebei, Peoples R China
[14] CSPC Pharmaceut Grp Co Ltd, Clin Div, Shijiazhuang, Hebei, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.644
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
614MO
引用
收藏
页码：S1624 / S1625
页数：3
相关论文
共 50 条
  • [31] Evaluation of Pneumonitis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Receiving Osimertinib and Thoracic Radiotherapy
    Mak, D. Y.
    Yan, M.
    Cheung, P.
    Parmar, A.
    Poon, I.
    Ung, Y. C.
    Tsao, M.
    Warner, A.
    Louie, A. V.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E380 - E381
  • [32] Pattern of Disease Progression on Osimertinib and Subsequent Treatment in Patients with EGFR-Mutated Non-Small Cell Lung Cancer
    Kim, H.
    Han, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1120 - S1120
  • [33] A phase II study of osimertinib in combination with platinum plus pemetrexed in patients with EGFR-mutated, advanced non-small cell lung cancer: The OPAL study (NEJ032C/LOGIK1801).
    Nakamura, Atsushi
    Saito, Ryota
    Ko, Ryo
    Azuma, Koichi
    Morita, Ryo
    Maemondo, Makoto
    Oizumi, Satoshi
    Takahashi, Kazuhisa
    Kagamu, Hiroshi
    Isobe, Takeshi
    Seike, Masahiro
    Kikuchi, Toshiaki
    Okamoto, Isamu
    Morita, Satoshi
    Asahina, Hajime
    Tanaka, Kentaro
    Sugio, Kenji
    Kobayashi, Kunihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [34] Concurrent osimertinib plus gefitinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC).
    Rotow, Julia K.
    Costa, Daniel Botelho
    Paweletz, Cloud P.
    Awad, Mark M.
    Marcoux, Paul
    Rangachari, Deepa
    Barbie, David Allen
    Sands, Jacob
    Cheng, Michael L.
    Johnson, Bruce E.
    Oxnard, Geoffrey R.
    Jackman, David Michael
    Kwiatkowski, David J.
    Kehl, Kenneth L.
    Izdebski, Monika D.
    Lau, Christie J.
    Vasquez, Kevin A.
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [35] EGFR mutation tracking predicts survival in advanced EGFR-mutated non-small cell lung cancer patients treated with osimertinib
    Buder, Anna
    Hochmair, Maximilian J.
    Setinek, Ulrike
    Pirker, Robert
    Filipits, Martin
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (02) : 239 - +
  • [36] Osimertinib in Relapsed EGFR-Mutated, T790M-Negative Non-Small Cell Lung Cancer (NSCLC) Patients: Results from the TREM-Study
    Eide, I. J.
    Helland, A.
    Borrisova, S.
    Ekman, S.
    Cicenas, S.
    Koivunen, J.
    Gronberg, B. H.
    Brustugun, O. T.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2140 - S2141
  • [37] Updated study results of pelcitoclax (APG-1252) in combination with osimertinib in patients (pts) with EGFR-mutant non-small cell lung cancer (NSCLC).
    Zhang, Li
    Zhao, Hongyun
    Zhao, Yanqiu
    Cheng, Ying
    Cui, Jiuwei
    Ma, Yuxiang
    Yang, Chen
    Zhang, Jie
    Xu, Liang
    Yu, Juan
    Men, Lichuang
    Liang, Zhiyan
    Yang, Dajun
    Zhai, Yifan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [38] Depression and Inflammation in Patients with EGFR-Mutated Non-Small Cell Lung Cancer
    Cardona, A.
    Arrieta, O.
    Rojas, L.
    Zatarain-Barron, Z.
    Ricaurte, L.
    Ruiz-Patino, A.
    Martin, C.
    Carranza, H.
    Vargas, C.
    Otero, J.
    Corrales, L.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S871 - S871
  • [39] Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer?
    Patel, Shruti R.
    Neal, Joel W.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (07) : 1631 - 1635
  • [40] Resistance mechanisms in EGFR-mutated advanced non-small cell lung cancer (aNSCLC) patients (pts) treated with first-line osimertinib (osi) and monitoring plasma mutational load: Preliminary results of REM study
    Bonanno, L.
    Ferro, A.
    Bao, L. C.
    Marinato, G. M.
    Padovan, A.
    Zulato, E.
    Frega, S.
    Dal Maso, A.
    Pasello, G.
    Indraccolo, S.
    Guarneri, V.
    ANNALS OF ONCOLOGY, 2023, 34
12345